Activation of pDCs at the Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

Trial Profile

Activation of pDCs at the Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs Resiquimod (Primary) ; Melanoma vaccine
  • Indications Malignant melanoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 18 Apr 2018 Results (n=47) assessing the biologic effects of Resiquimod, a TLR agonist that can activate both myeloid (TLR 8) and plasmacytoid (TLR 7) dendritic cells, on advanced stage melanoma, were presented at the 109th Annual Meeting of the American Association for Cancer Research.
    • 08 Jan 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top